Document is current
Any future updates will be listed below
-
Authors
Banks, Samantha A. https://orcid.org/0000-0002-5856-1367
Decker, Paul
Flanagan, Eoin P.
Zekeridou, Anastasia
Go, Ronald S. https://orcid.org/0000-0002-8284-3495
Abeykoon, Jithma P. https://orcid.org/0000-0003-3939-6252
Goyal, Gaurav
Young, Jason R. https://orcid.org/0000-0001-5351-8266
Koster, Matthew J.
Vassallo, Robert https://orcid.org/0000-0003-2328-0255
Ryu, Jay H. https://orcid.org/0000-0002-9576-2272
Davidge-Pitts, Caroline J.
Ravindran, Aishwarya
Sartori Valinotti, Julio C.
Bennani, N. Nora https://orcid.org/0000-0001-8358-5953
Shah, Mithun V. https://orcid.org/0000-0002-5359-336X
Rech, Karen L. https://orcid.org/0000-0001-6770-2339
Bach, Corrie R.
Eckel-Passow, Jeanette E.
Tobin, W. Oliver https://orcid.org/0000-0002-8141-2394
,
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1 TR002377)
- License Information
-
More Information
Article History
Received: 18 June 2024
Revised: 24 July 2024
Accepted: 29 July 2024
First Online: 5 September 2024
Competing interests
: Dr. Banks was supported by Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH; Dr Flanagan has served on advisory boards for Alexion, Genentech, Horizon Therapeutics and UCB. He has received research support from UCB, he has received speaker honoraria from Pharmacy Times, he received royalties from UpToDate, he is a site principal investigator in a randomized clinical trial of Rozanolixizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by UCB and is a site principal investigator and a member of the steering committee for a clinical trial of satralizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by Roche/Genentech, he has received funding from the NIH (R01NS113828), he is a member of the medical advisory board of the MOG project and is an editorial board member of Neurology, Neuroimmunology and Neuroinflammation, The Journal of the Neurological Sciences and Neuroimmunology Reports, a patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity; Dr. Zekeridou reports patents submitted for PDE10A-IgG, DACH1-IgG and Tenascin-R-IgG as biomarkers of neurological paraneoplastic autoimmunity, research funding from Roche not related to this project and consulting for Alexion Pharmaceuticals without personal compensation; Dr. Tobin reports receiving research funding from the National institutes of Health, Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology and Mallinckrodt Inc, he receives royalties from the publication of “Mayo Clinic Cases in Neuroimmunology” (OUP); Paul Decker, Ronald Go, Jithma Abeykoon, Gaurav Goyal, Jason Young, Matthew Koster, Robert Vassallo, Jay Ryu, Caroline Davidge-Pitts, Aishwarya Ravindran, Julio Sartori Valinotti, Nora Bennani, Mithun Shah, Corrie Bach, Jeanette Eckel-Passow declare no competing interests.
